ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Theravance Biopharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Theravance Biopharma. The consolidated Growth Rank has a good rank of 53, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 53% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 73, which means that professional investors are more optimistic about the stock than for 73% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 9, which means that the share price of Theravance Biopharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 91% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 42, which means that the company has a financing structure that is riskier than those of 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more